bullish

CanSino Biologics (6185.HK/688185.CH) - Breakeven May Arrive Earlier than Expected

327 Views23 Oct 2024 08:55
​CanSino 24H1 results beat expectation due to strong CDMO revenue/effective cost control/increased MCV demand. PCV13i approval would be faster-than-expected. Reasonable market value is RMB5-10 billion
What is covered in the Full Insight:
  • Introduction
  • Financial Performance Update
  • Vaccine Portfolio and Market Expansion
  • Cost Management and Operational Efficiency
  • Future Outlook and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
x